Pseudomonas aeruginosa is a bacterial species capable of causing infection, particularly in vulnerable patients and healthcare settings. A DNA finding in stool is a different type of evidence from a clinical specimen collected from an infected wound, lung or bloodstream.
On this page
Why the infection site matters
CDC describes P. aeruginosa infections in several parts of the body and highlights the importance of antibiotic resistance. Diagnosis and treatment depend on the affected site and appropriate laboratory testing. A stool result cannot identify a lung or bloodstream infection. [1]
What GI-MAP measures
The panel contains a P. aeruginosa target separate from the broader Pseudomonas spp. line. Detection identifies targeted DNA in the submitted stool. It does not show that the organism is alive, invading tissue or responsible for current symptoms. [2]
How to interpret a high value
A high flag is relative to the assay’s reference range, not a validated score of infection severity. Review immune status, recent hospital care, antibiotics and the actual symptom pattern with a clinician. A species count cannot predict resistance to a particular antibiotic.
If a separate culture has found P. aeruginosa, keep that report and its susceptibility results available. Do not substitute the GI-MAP number for the clinical culture or assume a falling stool number proves that another infection has resolved.
When clinical assessment matters more than the panel
Fever with significant illness, breathing difficulty or a worsening wound needs timely medical assessment. People with weakened immune systems should contact their care team promptly about concerning symptoms. A stool panel is not a substitute for that evaluation. [1]
Common questions
Is detection in stool always an infection?
No. Detection and clinical infection are different conclusions; symptoms, specimen type and further evidence matter.
Can an undetected stool result rule out P. aeruginosa elsewhere?
No. It addresses that stool sample, not every body site.
Sources and review
Sources checked October 7, 2026. Manufacturer material describes the test; clinical guidance and research support the interpretation limits.
- CDC: About Pseudomonas aeruginosa
- Diagnostic Solutions Laboratory: GI-MAP interpretive guide (manufacturer specifications)
Medical review of this article is pending. For a correction or source question, contact GI MAP Test.